Stock Events

Stock Events

Verici Dx 

$0.003000
12
+$0.00+0% Thursday 20:00

Statistics

Day High
2.91
Day Low
2.91
52W High
2.91
52W Low
0.003
Volume
200
Avg. Volume
0
Mkt Cap
4.54M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14SepExpected
Q2 2024
Q1 2025
Q1 2025
Q2 2025
Q1 2026
Next
-0.01
-0
-0
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-189.22%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.66MRevenue
-6.93MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow VRCDF. It's not an investment recommendation.
Alphabet
5
GOOGL
Vanguard S&P 500 UCITS - Dist
5
VUSA.LSE
Rolls-Royce
5
RR.LSE
Apple
4
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap21.67B
Guardant Health, Inc. provides liquid biopsy tests, competing in the broader diagnostic and personalized medicine space alongside Verici Dx.
Natera
NTRA
Mkt Cap47.03B
Fulgent Genetics
FLGT
Mkt Cap539.57M
Fulgent Genetics, Inc. provides comprehensive genetic testing, competing in the genetic diagnostics market alongside Verici Dx.
QuidelOrtho
QDEL
Mkt Cap1.01B
QuidelOrtho Corporation specializes in diagnostic testing solutions, including those for transplant monitoring, competing with Verici Dx's offerings.
Myriad Genetics
MYGN
Mkt Cap302.25M
Myriad Genetics, Inc. provides genetic tests for cancer and other conditions, directly competing in the personalized medicine and diagnostics market.
Pacific Biosciences of California
PACB
Mkt Cap435.16M
Pacific Biosciences of California, Inc. offers sequencing solutions that can be used in diagnostic applications, indirectly competing with Verici Dx.
Illumina
ILMN
Mkt Cap32.55B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, indirectly competing in the diagnostics and research market relevant to Verici Dx.

About

Verici Dx plc is an immuno-diagnostics developer primarily dedicated to innovations within the kidney transplantation field. It creates both prognostic (predictive) and diagnostic (identifying current conditions) assays specifically designed for kidney transplant recipients. Its developmental pipeline currently features several key tests: Clarava, a pre-transplant prognostic tool designed to assess the risk of early acute rejection. Tuteva, a post-transplant solution focused on identifying acute cellular rejection. Protega, a novel liquid biopsy that aims to predict the future risk of fibrosis and long-term graft failure. Established in 2020, the company operates from its base in Penarth, United Kingdom.
Show more...
CEO
Sara jane Barrington
Employees
19
Country
United Kingdom
ISIN
GB00BM8HZD43
WKN
000A2QGXF

Listings

STU
DE
63V.STU
F
DE
63V.F
LSE
GB
VRCI.LSE
OTC Link
US
VRCDF

0 Comments

Share your thoughts

FAQ

What is Verici Dx stock price today?▼
The current price of VRCDF is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Verici Dx stock price performance more closely on the chart.
What is Verici Dx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Verici Dx stocks are traded under the ticker VRCDF.
What is Verici Dx market cap?▼
Today Verici Dx has the market capitalization of 4.54M
When is the next Verici Dx earnings date?▼
Verici Dx is going to release the next earnings report on September 14, 2026.
What is Verici Dx revenue for the last year?▼
Verici Dx revenue for the last year amounts to 3.66M USD.
What is Verici Dx net income for the last year?▼
VRCDF net income for the last year is -6.93M USD.
How many employees does Verici Dx have?▼
As of September 04, 2026, the company has 19 employees.
In which sector is Verici Dx located?▼
Verici Dx operates in the Health & Wellness sector.
When did Verici Dx complete a stock split?▼
Verici Dx has not had any recent stock splits.
Where is Verici Dx headquartered?▼
Verici Dx is headquartered in Penarth, United Kingdom.